Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023 Eisai Jan 18, 2023 12:28 HKT/SGT Read More
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan Eisai Jan 16, 2023 17:56 HKT/SGT Read More
Fujitsu and Sapporo Medical University launch joint project to realize data portability in the healthcare field Fujitsu Ltd Jan 16, 2023 10:17 HKT/SGT Read More
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において早期アルツハイマー病に係る適応で新薬承認を申請 Eisai Jan 16, 2023 09:00 JST Read More
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 PCG Digital Jan 16, 2023 06:00 HKT/SGT Read More
American Green (OTC:ERBB) Architectural Plans for Its 40,000 s.f. Cypress Chill Cannabis Grow are in the Final Review Phase American Green, Inc Jan 13, 2023 09:00 HKT/SGT Read More
NLS Pharmaceutics、同社の成長を続ける前臨床化合物ポートフォリオをレビューするR&Dアップデート ウェブキャストを開催 NLS Pharmaceutics Ltd. Jan 13, 2023 09:00 JST Read More
Research commenced with Keio University to discover drugs using "Chemicals Informatics" Hitachi, Ltd. Jan 12, 2023 12:29 HKT/SGT Read More
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe Eisai Jan 11, 2023 11:52 HKT/SGT Read More
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、欧州において早期アルツハイマー病に係る適応で販売承認申請を提出 Eisai Jan 11, 2023 09:00 JST Read More
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease Eisai Jan 09, 2023 20:55 HKT/SGT Read More
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease Eisai Jan 09, 2023 19:40 HKT/SGT Read More
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、中国において、生物製剤ライセンス申請のデータ提出を開始 Eisai Dec 23, 2022 08:40 JST Read More
